Press Releases Archives | Page 2 of 5

Press Releases

MaaT Pharma Treats First Acute Myeloid Leukemia Patient in Phase 1 Clinical Trial to Evaluate Capsule Formulation of Microbiome Restoration Biotherapeutic

MaaT033 is an oral formulation of MaaT Pharma’s full-ecosystem biotherapeutic characterized by high microbial diversity and richness Study will evaluate safety, dosing regimen and activity of MaaT033 in patients with acute myeloid leukemia receiving intensive chemotherapy Lyon,…

MaaT PharmaNovember 12, 2020

Press Releases

MaaT Pharma Announces Positive Data for its Lead Microbiome Biotherapeutic MaaT013 in Intestinal Acute Graft-versus-Host-Disease at the Virtual 46th Annual Meeting of the EBMT

-- Clinical data was gathered from eleven patients with gastrointestinal (GI) aGvHD treated with MaaT013,…

MaaT PharmaAugust 31, 2020

Press Releases

MaaT Pharma to Announce Clinical Data with its Lead Microbiota Biotherapeutic in Intestinal Acute GvHD at Virtual 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)

-- Data from the Company’s compassionate use program with MaaT013 as a treatment in patients…

MaaT PharmaAugust 28, 2020

Press Releases

MaaT Pharma Appoints Savita Bernal as Chief Business Officer

Lyon, France, May 28, 2020 – MaaT Pharma announced today that Savita Bernal, PhD, has…

MaaT PharmaMay 28, 2020

Press Releases

MaaT Pharma Announces Formation of Its GvHD-focused Scientific Advisory Board to Support Development of Microbiome Restoration Therapeutics in Hemato-oncological Indications

Lyon, France, May 12, 2020 – MaaT Pharma announced today the appointment of leading international…

MaaT PharmaMay 12, 2020

Press Releases

MaaT Pharma Annonce 18 millions d’euros de Financement Série B pour l’Expansion de son Développement Clinique de Médicaments Biologiques « Microbiote »

Lyon, le 5 février 2020 - MaaT Pharma annonce aujourd'hui une levée de fonds de…

MaaT PharmaFebruary 4, 2020

Press Releases

MaaT Pharma Announces €18 Million Series B Financing Round to Support Further Clinical Development of Microbiome Biotherapeutics

Lyon, France, February 5, 2020 – MaaT Pharma announced today an €18 million Series B…

MaaT PharmaJanuary 31, 2020

Press Releases

MaaT Pharma announces the presentation of data with its Lead Microbiota Biotherapeutic in intestinal GvHD at 61st American Society of Hematology (ASH) Annual Meeting

Lyon, France, November 6, 2019 – MaaT Pharma announced today that a poster will…

MaaT PharmaNovember 6, 2019

Press Releases

MaaT Pharma Expands Executive Team to Strengthen Corporate Development and Accelerate Expansion of Microbiome Data Science Platform GutPrint

Jean-Marc Renard, MS, MBA, joins as Chief Business Officer Emmanuel Prestat, PhD, joins as Computational…

MaaT PharmaSeptember 10, 2019

Press Releases

MaaT Pharma Completes Third Positive DSMB Assessment Setting High Safety Standard for Human Intestinal Microbiome Whole Ecosystem-Based Therapeutics

Independent Data Safety Monitoring Board (DSMB) confirms continuation of Phase II HERACLES study in acute…

MaaT PharmaJune 24, 2019

Press Releases

MaaT Pharma Treats First Acute Myeloid Leukemia Patient in Phase 1 Clinical Trial to Evaluate Capsule Formulation of Microbiome Restoration Biotherapeutic

MaaT Pharma Announces Positive Data for its Lead Microbiome Biotherapeutic MaaT013 in Intestinal Acute Graft-versus-Host-Disease at the Virtual 46th Annual Meeting of the EBMT

MaaT Pharma to Announce Clinical Data with its Lead Microbiota Biotherapeutic in Intestinal Acute GvHD at Virtual 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)

MaaT Pharma Appoints Savita Bernal as Chief Business Officer

MaaT Pharma Announces Formation of Its GvHD-focused Scientific Advisory Board to Support Development of Microbiome Restoration Therapeutics in Hemato-oncological Indications

MaaT Pharma Annonce 18 millions d’euros de Financement Série B pour l’Expansion de son Développement Clinique de Médicaments Biologiques « Microbiote »

MaaT Pharma Announces €18 Million Series B Financing Round to Support Further Clinical Development of Microbiome Biotherapeutics

MaaT Pharma announces the presentation of data with its Lead Microbiota Biotherapeutic in intestinal GvHD at 61st American Society of Hematology (ASH) Annual Meeting

MaaT Pharma Expands Executive Team to Strengthen Corporate Development and Accelerate Expansion of Microbiome Data Science Platform GutPrint

MaaT Pharma Completes Third Positive DSMB Assessment Setting High Safety Standard for Human Intestinal Microbiome Whole Ecosystem-Based Therapeutics

Categories

MAAT PHARMA

COMPANY

RESSOURCES

CONTACT